BDBM660424 US20240092799, Compound XXIX-AN::US20240092799, Compound XXIX-D

SMILES Cc3cc(Nc2cc(Nc1ccccn1)ncn2)[n+]([O-])c4c3C(=O)NC45CCCCC5

InChI Key InChIKey=ZBSIZCILWFDMMG-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 660424   

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660424(US20240092799, Compound XXIX-AN | US20240092799, C...)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660424(US20240092799, Compound XXIX-AN | US20240092799, C...)
Affinity DataIC50: 1.00E+3nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent